News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Avera McKennan Cancer Institute Chooses Intraop Medical Corporation (IOPM)'s Mobetron for Breast Cancer Care

5/26/2010 1:21:58 PM

SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation (Pink Sheets: IOPD) today announced that Avera McKennan Cancer Institute has chosen to install a Mobetron for treating breast cancer in its Sioux Falls, South Dakota facility.

IntraOp’s Mobetron is a mobile technology that delivers IOERT to a tumor site during cancer surgery. The Mobetron enables radiation and surgical oncologists to visually pinpoint the optimal site for radiation by seeing the exposed tumor bed and delivering a concentrated radiation dose during cancer surgery. Since the Mobetron is a mobile, self-shielded device, doctors are able to move the Mobetron among different operating rooms to more efficiently treat a greater number of patients.

IOERT, traditionally used for treatment of advanced and recurrent disease, is increasingly demonstrating its effectiveness in fighting breast cancer. As a boost dose to a regular course of radiation treatment, IOERT has been shown to reduce 5-year cancer recurrence rates, while increasing expected patient survival. As a single dose, IOERT may also be able to replace the traditional regimen of radiation for some women, thereby eliminating the need for 6 weeks of post operative radiation treatment. This has the benefit to the patient of reducing overall treatment time and increasing her quality of life. An additional benefit is that the reduction in post-operative radiation treatments will reduce drive time for Avera’s rural patient population base, which will help increase therapy completion rates. Dr. Wade Dosch, a physician involved in the project, explained the value of the treatment for Avera’s patients, “It is heartbreaking to watch a woman choose to have a mastectomy because she cannot tolerate the time commitment required of radiation therapy after breast conservation. Offering a treatment that will decrease post-operative radiation visits will help women decide to pursue breast conservation instead of mastectomy."

This will be the 12th Mobetron installed in the United States, and the 34th worldwide. John Powers, CEO of IntraOp commented, “We are very pleased that Avera McKennan has chosen to use the Mobetron for its cancer care facility. We are seeing a growing interest within the US and across the globe in implementing this incredibly beneficial technology."

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intra-operative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielding intra-operative electron radiation therapy device designed for use in any operating room or office setting. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Read at

comments powered by Disqus